Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation
- PMID: 12091808
- DOI: 10.1067/mtc.2002.121293
Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation
Abstract
Objective: The effects of cell transplantation on the ischemic failing heart have already been documented. However, the area in and around infarct regions is not a good environment for cells to survive in because they are exposed to poor conditions in which certain requirements cannot be adequately supplied. We therefore designed a study to investigate the efficacy of prevascularization in ischemic regions before cell transplantation.
Methods: Rats with myocardial infarction were randomized into 4 groups: 11 rats received a culture medium injection to the left ventricular wall (control group), 11 received fetal cardiomyocyte transplantation (TX group), 11 received gelatin hydrogel microspheres incorporating basic fibroblast growth factor (FGF group), and 11 received basic fibroblast growth factor pretreatment sequentially, followed by cardiomyocyte transplantation (FGF-TX group). Four weeks later, left ventricular function was assessed by means of echocardiography and cardiac catheterization.
Results: In the FGF and FGF-TX groups neovascularization was found in the scar tissue 1 week later. The TX, FGF, and FGF-TX groups showed better fractional shortening than the control group (TX, FGF, FGF-TX, and control: 28% +/- 4.4%, 24% +/- 8.6%, 27% +/- 7.3%, and 17% +/- 4.6%, respectively; P <.01). Left ventricular maximum time-varying elastance was higher in the FGF-TX group than in the TX and FGF groups (FGF-TX, TX, and FGF: 0.52 +/- 0.23, 0.30 +/- 0.08, and 0.27 +/- 0.20 mm Hg/microL, respectively; P <.01). Histologically, more transplanted cells survived in the FGF-TX group than in the TX group.
Conclusions: Prevascularization with basic fibroblast growth factor-incorporated microspheres enhances the benefits of cardiomyocyte transplantation. We expect that this system will contribute to regeneration medicine through its extensive application to other growth factors.
Similar articles
-
Improved therapeutic efficacy in cardiomyocyte transplantation for myocardial infarction with release system of basic fibroblast growth factor.Artif Organs. 2003 Feb;27(2):181-4. doi: 10.1046/j.1525-1594.2003.06993.x. Artif Organs. 2003. PMID: 12580776
-
Cardiomyocyte transplantation does not reverse cardiac remodeling in rats with chronic myocardial infarction.Ann Thorac Surg. 2002 Jul;74(1):25-30. doi: 10.1016/s0003-4975(02)03601-9. Ann Thorac Surg. 2002. PMID: 12118775
-
Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model.Heart Vessels. 2003 May;18(2):93-9. doi: 10.1007/s10380-002-0686-5. Heart Vessels. 2003. PMID: 12756606
-
[Cardiomyocyte transplantation--a cell replacement for repair of myocardial infarction?].Z Kardiol. 1998 Jan;87(1):1-7. doi: 10.1007/s003920050147. Z Kardiol. 1998. PMID: 9531693 Review. German.
-
Clinical application of injectable growth factor for bone regeneration: a systematic review.Inflamm Regen. 2019 Oct 22;39:20. doi: 10.1186/s41232-019-0109-x. eCollection 2019. Inflamm Regen. 2019. PMID: 31660090 Free PMC article. Review.
Cited by
-
Novel therapeutic approach for pulmonary emphysema using gelatin microspheres releasing basic fibroblast growth factor in a canine model.Surg Today. 2014 Aug;44(8):1536-41. doi: 10.1007/s00595-014-0864-x. Epub 2014 Feb 18. Surg Today. 2014. PMID: 24535698
-
Biomaterial technology for tissue engineering applications.J R Soc Interface. 2009 Jun 6;6 Suppl 3(Suppl 3):S311-24. doi: 10.1098/rsif.2008.0448.focus. Epub 2009 Mar 4. J R Soc Interface. 2009. PMID: 19324684 Free PMC article. Review.
-
Myoblast-based cell transplantation.Heart Fail Rev. 2003 Jul;8(3):221-7. doi: 10.1023/a:1024705214292. Heart Fail Rev. 2003. PMID: 12878830 Review.
-
Prevention of tooth extraction-triggered bisphosphonate-related osteonecrosis of the jaws with basic fibroblast growth factor: An experimental study in rats.PLoS One. 2019 Feb 8;14(2):e0211928. doi: 10.1371/journal.pone.0211928. eCollection 2019. PLoS One. 2019. PMID: 30735554 Free PMC article.
-
Treatment of experimental osteonecrosis of the hip in adult rabbits with a single local injection of recombinant human FGF-2 microspheres.J Bone Miner Metab. 2010 Nov;28(6):608-16. doi: 10.1007/s00774-010-0172-5. Epub 2010 Mar 31. J Bone Miner Metab. 2010. PMID: 20354742
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical